Personal information

Emails & domains

Verified email domains

Other IDs

ResearcherID: N-4078-2013

Activities

Collapse all

Employment (3)

Vall d'Hebron Institute of Oncology (VHIO): Barcelona, Catalunya, ES

2017-06-01 to present | Miguel Servet Researcher (Assistant Professor) (Oncology, Gastrointestinal and Endocrine Group)
Employment
Source: Self-asserted source
Rodrigo Toledo

Centro Nacional de Investigaciones Oncológicas: Madrid, Madrid, ES

2014-11-01 to 2017-05-30 | Researcher (Clinical Research)
Employment
Source: Self-asserted source
Rodrigo Toledo

University of Texas Health Science Center at San Antonio: San Antonio, TX, US

2011-07-01 to 2013-11-30 | Postdoc Fellow (Medicine)
Employment
Source: Self-asserted source
Rodrigo Toledo

Education and qualifications (4)

Universidade de Sao Paulo Campus da Capital: Sao Paulo, SP, BR

2008-02-01 to 2011-11-30 | Bachelor in Biomedicine
Education
Source: Self-asserted source
Rodrigo Toledo

Universidade de Sao Paulo Campus da Capital: Sao Paulo, SP, BR

2007-12-01 to 2010-11-30 | PhD Doctorate degree (Cancer Genetics)
Education
Source: Self-asserted source
Rodrigo Toledo

Universidade de Sao Paulo Campus da Capital: Sao Paulo, SP, BR

2004-02-01 to 2007-11-30 | Master in Science (Cancer Genetics)
Education
Source: Self-asserted source
Rodrigo Toledo

Universidade de Sao Paulo Campus da Capital: Sao Paulo, SP, BR

1999-02-01 to 2003-11-30 | Bachelor of Science in Biology
Education
Source: Self-asserted source
Rodrigo Toledo

Works (50 of 90)

Items per page:
Page 1 of 2

Data from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.c.7020886.v1
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

Data from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.c.7020886
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

FIGURE 1 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982258
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

FIGURE 1 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982258.v1
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

FIGURE 2 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982255
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

FIGURE 2 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982255.v1
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

FIGURE 3 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982252.v1
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

FIGURE 3 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982252
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

FIGURE 4 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982249.v1
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

FIGURE 4 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982249
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

Figure S1 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982246
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

Figure S1 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982246.v1
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

Figure S2 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982243
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

Figure S2 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982243.v1
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

TABLE 1 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982240
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

TABLE 1 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982240.v1
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

Table S1 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982237
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

Table S1 from Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

2024-01-11 | Preprint
DOI: 10.1158/2767-9764.24982237.v1
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression

Cancer Research Communications
2024-01-11 | Journal article
DOI: 10.1158/2767-9764.CRC-23-0287
Contributors: Marta Ligero; Garazi Serna; Omar S.M. El Nahhas; Irene Sansano; Siarhei Mauchanski; Cristina Viaplana; Julien Calderaro; Rodrigo A. Toledo; Rodrigo Dienstmann; Rami S. Vanguri et al.
Source: check_circle
Crossref

Predictive Impact of RNF43 Mutations in Patients With Proficient Mismatch Repair/Microsatellite Stable BRAFV600E-Mutated Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy

JCO Precision Oncology
2023-09 | Journal article
DOI: 10.1200/PO.23.00255
Contributors: Roberto Moretto; Marco Maria Germani; Javier Ros; Francesca Daniel; Filippo Ghelardi; Guglielmo Vetere; Mirella Giordano; Rodrigo De Almeida Toledo; Francesca Bergamo; Giovanni Randon et al.
Source: check_circle
Crossref

Longitudinal whole-exome sequencing of cell-free DNA for tracking the co-evolutionary tumor and immune evasion dynamics: longitudinal data from a single patient

Annals of Oncology
2021-05 | Journal article
DOI: 10.1016/j.annonc.2021.02.007
Part of ISSN: 0923-7534
Source: Self-asserted source
Rodrigo Toledo

Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.

Journal of Clinical Oncology
2020-05-20 | Journal article
DOI: 10.1200/jco.2020.38.15_suppl.4112
Part of ISSN: 0732-183X
Part of ISSN: 1527-7755
Source: Self-asserted source
Rodrigo Toledo

Recognizing hypoxia in phaeochromocytomas and paragangliomas

Nature Reviews Endocrinology
2020-04-11 | Journal article
DOI: 10.1038/s41574-020-0324-1
Contributors: Patricia L. M. Dahia; Rodrigo A. Toledo
Source: check_circle
Crossref

Genotype and phenotype landscape of MEN2 in 554 medullary thyroid cancer patients: the BrasMEN study

Endocrine Connections
2019-03 | Journal article
DOI: 10.1530/ec-18-0506
Part of ISSN: 2049-3614
Source: Self-asserted source
Rodrigo Toledo

Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer

American Journal of Clinical Oncology
2019-01 | Journal article
DOI: 10.1097/coc.0000000000000474
Part of ISSN: 0277-3732
Source: Self-asserted source
Rodrigo Toledo

Germline mutation landscape of multiple endocrine neoplasia type 1 using full gene next-generation sequencing

European Journal of Endocrinology
2018-12 | Journal article
DOI: 10.1530/eje-18-0430
Part of ISSN: 0804-4643
Part of ISSN: 1479-683X
Source: Self-asserted source
Rodrigo Toledo

Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies

Clinical Cancer Research
2018-08-01 | Journal article
DOI: 10.1158/1078-0432.ccr-18-0103
Part of ISSN: 1078-0432
Part of ISSN: 1557-3265
Source: Self-asserted source
Rodrigo Toledo

Inflated pathogenic variant profiles in the ClinVar database

Nature Reviews Endocrinology
2018-07 | Journal article
DOI: 10.1038/s41574-018-0034-0
Contributors: Rodrigo A. Toledo
Source: check_circle
Crossref

Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors

F1000Research
2018-07-30 | Journal article
DOI: 10.12688/f1000research.13995.1
Part of ISSN: 2046-1402
Source: Self-asserted source
Rodrigo Toledo

EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease

New England Journal of Medicine
2018-03-29 | Journal article
DOI: 10.1056/nejmc1716652
Part of ISSN: 0028-4793
Part of ISSN: 1533-4406
Source: Self-asserted source
Rodrigo Toledo

New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas

Endocrine-Related Cancer
2017-09 | Journal article
DOI: 10.1530/erc-16-0479
Part of ISSN: 1351-0088
Part of ISSN: 1479-6821
Source: Self-asserted source
Rodrigo Toledo

The penetrance of MEN2 pheochromocytoma is not only determined by RET mutations

Endocrine-Related Cancer
2017-08 | Journal article
DOI: 10.1530/erc-17-0189
Part of ISSN: 1351-0088
Part of ISSN: 1479-6821
Source: Self-asserted source
Rodrigo Toledo

Whole-exome sequencing of plasma cell-free DNA portrays the somatic mutation landscape of refractory metastatic colorectal cancer and enables the discovery of mutatedKDR/VEGFR2 receptors as modulators of anti-angiogenic therapies

2017-08-17 | Preprint
DOI: 10.1101/177287
Contributors: Rodrigo A. Toledo; Elena Garralda; Maria Mitsi; Tirso Pons; Jorge Monsech; Estela Vega; Álvaro Otero; Maria I. Albarran; Natalia Baños; Yolanda Durán et al.
Source: check_circle
Crossref

Genetics of Pheochromocytomas and Paragangliomas

Endocrinology and Metabolism Clinics of North America
2017-06 | Journal article
DOI: 10.1016/j.ecl.2017.01.009
Part of ISSN: 0889-8529
Source: Self-asserted source
Rodrigo Toledo

Assessment of Depression, Anxiety, Quality of Life, and Coping in Long-Standing Multiple Endocrine Neoplasia Type 2 Patients

Thyroid
2017-05 | Journal article
DOI: 10.1089/thy.2016.0148
Part of ISSN: 1050-7256
Part of ISSN: 1557-9077
Source: Self-asserted source
Rodrigo Toledo

Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab

Oncotarget
2017-05-23 | Journal article
DOI: 10.18632/oncotarget.13311
Part of ISSN: 1949-2553
Source: Self-asserted source
Rodrigo Toledo

Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas

Nature Reviews Endocrinology
2017-04 | Journal article
DOI: 10.1038/nrendo.2016.185
Part of ISSN: 1759-5029
Part of ISSN: 1759-5037
Source: Self-asserted source
Rodrigo Toledo

Neoplasias Endócrinas Múltiplas

Cĺınica Médica [2ed. ampl. rev.]
2016 | Journal article
Source: Self-asserted source
Rodrigo Toledo

Next-Generation Sequencing: Validating Desktop Sequencer As a Cost-Effective Tool to Genetic Screening of Multiple Endocrine Neoplasia Type 1 Index Cases

Metastasis and Tumor Progression, Neoplasia of Endocrine Tissue, Therapies for Cancer, and Tumorigenesis (posters)
2016 | Book chapter
Source: Self-asserted source
Rodrigo Toledo

Psychological Harm and Quality of Life in Patients with Multiple Endocrine Neoplasia Type 2

Metastasis and Tumor Progression, Neoplasia of Endocrine Tissue, Therapies for Cancer, and Tumorigenesis (posters)
2016 | Book chapter
Source: Self-asserted source
Rodrigo Toledo

Recurrent mutations of chromatin-remodeling genes and kinase receptors in pheochromocytomas and paragangliomas

Clinical Cancer Research
2016 | Journal article
Source: Self-asserted source
Rodrigo Toledo

Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility

Endocrine-related cancer
2015 | Journal article
Source: Self-asserted source
Rodrigo Toledo

Integrity of the pheochromocytoma susceptibility TMEM127 gene in patients with pediatric malignancies

Endocrine-related cancer
2015 | Journal article
Source: Self-asserted source
Rodrigo Toledo

Next-generation sequencing for the diagnosis of hereditary pheochromocytoma and paraganglioma syndromes

Current Opinion in Endocrinology & Diabetes and Obesity
2015 | Journal article
Source: Self-asserted source
Rodrigo Toledo

RET Y791F Variant Does Not Increase the Risk for Medullary Thyroid Carcinoma

Thyroid
2015 | Journal article
Source: Self-asserted source
Rodrigo Toledo

RET Y791F: alone or accompanied?

Archives of endocrinology and metabolism
2015 | Journal article
Source: Self-asserted source
Rodrigo Toledo

Association between the p27 rs2066827 variant and tumor multiplicity in patients harboring MEN1 germline mutations

European Journal of Endocrinology
2014 | Journal article
Source: Self-asserted source
Rodrigo Toledo

Growth hormone (GH) response to growth hormone-releasing peptide-2 in GH-deficient little mouse

Arquivos Brasileiros de Endocrinologia e Metabologia
2014 | Journal article
Source: Self-asserted source
Rodrigo Toledo

Next-generation sequencing for the genetic screening of phaeochromcytomas and paragangliomas: riding the new wave, but with caution

Clinical endocrinology
2014 | Journal article
Source: Self-asserted source
Rodrigo Toledo

Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study

The Lancet Oncology
2014 | Journal article
Source: Self-asserted source
Rodrigo Toledo
Items per page:
Page 1 of 2
How many people are using ORCID?